Search - tctmd.com

Displaying 161 - 180 of 5003

Sort: Relevancy | Date

News Daily News

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

Shelley Wood

October 07, 2016

News Daily News

EUCLID:替卡格雷相比氯吡格雷对有症状 PAD 患者预防心血管事件没有更大的好处

Shelley Wood

October 07, 2016

News Daily News

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Shelley Wood

October 07, 2016

News Daily News

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

Shelley Wood

October 07, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

Vascular Solutions 召回双通双通路导管

Michael O'Riordan

October 06, 2016

News Daily News

Vascular Solutions Retira los Catéteres Gemelos de Doble Vía

Michael O'Riordan

October 06, 2016

News Daily News

Vascular Solutions Recalls Twin-Pass Dual-Access Catheters

Michael O'Riordan

October 06, 2016

News Daily News

Low Diastolic Blood Pressure Linked to Subclinical Myocardial Damage and Coronary Events: ARIC Analysis

Michael O'Riordan

October 06, 2016

News Daily News

Location Matters: Getting Acute MI Care at a High-Quality Hospital Has Lasting Benefits

Todd Neale

October 06, 2016

News Daily News

STEMI 患者 CTO PCI 前沿：EXPLORE 带来更多问题

Yael L. Maxwell

October 05, 2016

News Daily News

STEMI Patients Far From PCI Centers Fare Well With Pharmacoinvasive Strategy

L.A. McKeown

October 05, 2016

News Daily News

On the Frontier of CTO PCI for STEMI Patients: Answers Lead to More Questions in EXPLORE

Yael L. Maxwell

October 05, 2016

News Daily News

En la Frontera de las PCI para el Manejo de OTC para Pacientes STEMI: Las Respuestas Llevan a Más Preguntas en el EXPLORE

Yael L. Maxwell

October 05, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

In Print at Last, Early Cardioband Results Show Safety, Feasibility at 6 Months

Shelley Wood

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

比伐卢定和普通肝素对有无 ST 段抬高的 ACS 患者没有任何差异：MATRIX

Shelley Wood

October 03, 2016

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

Advertisement

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

EUCLID:替卡格雷相比氯吡格雷对有症状 PAD 患者预防心血管事件没有更大的好处

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Vascular Solutions 召回双通双通路导管

Vascular Solutions Retira los Catéteres Gemelos de Doble Vía

Vascular Solutions Recalls Twin-Pass Dual-Access Catheters

Low Diastolic Blood Pressure Linked to Subclinical Myocardial Damage and Coronary Events: ARIC Analysis

Location Matters: Getting Acute MI Care at a High-Quality Hospital Has Lasting Benefits

STEMI 患者 CTO PCI 前沿：EXPLORE 带来更多问题

STEMI Patients Far From PCI Centers Fare Well With Pharmacoinvasive Strategy

On the Frontier of CTO PCI for STEMI Patients: Answers Lead to More Questions in EXPLORE

En la Frontera de las PCI para el Manejo de OTC para Pacientes STEMI: Las Respuestas Llevan a Más Preguntas en el EXPLORE

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

In Print at Last, Early Cardioband Results Show Safety, Feasibility at 6 Months

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

比伐卢定和普通肝素对有无 ST 段抬高的 ACS 患者没有任何差异：MATRIX

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content